Only one from every two adult sufferers survive acute myeloid leukaemia.

The assumption is that leukaemic stem cells, which cannot be totally eliminated during treatment, will be the origin of relapse. However, as has been discovered by a united team of Frankfurt-based researchers, these cells do possess a weakness: In today’s edition of the high effect journal ‘Cancer Research’, they record that the enzyme 5-lipoxygenase plays a significant function in the survival of leukaemic AML stem cells. Related StoriesSausages With Antioxidants From Berries To Prevent CancerFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLCViralytics enters into medical trial collaboration contract with MSD5-LO is well known for its role in inflammatory illnesses like asthma.Steindler, executive director of the McKnight Human brain Institute. He is not only going to complement our existing programs, he will create new ones that will enable us to target all neurological disorders. His experience in medication discovery and expertise in transforming laboratory discoveries into clinical therapies and diagnostics will become welcome, relating to Tetsuo Ashizawa, M.D., chairman of the section of neurology. That is an extraordinary fit with a number of our experts fighting to get rid of neurodegenerative diseases and cognitive decline, Ashizawa said. My excitement is based on the collaborations and fresh relationships that we will build, and how that may enrich the scientific and translational research in the neurology department.